The Potential for Fighting Sepsis with Vaccines
Dr. Jan Poolman, Head Bacterial Vaccine Discovery and Early Development at Janssen Infectious Diseases and Vaccines, at the Janssen Pharmaceutical Companies of Johnson & Johnson discusses the risks and burdens associated with sepsis and the evaluation of vaccine candidates to potentially protect against life-threatening bacterial infections.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Vaccine. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Vaccine and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Vaccine?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Dr. Jan Poolman is Head Bacterial Vaccine Discovery and Early Development at Janssen Infectious Diseases and Vaccines, at the Janssen Pharmaceutical Companies of Johnson & Johnson. Jan leads the bacterial vaccines team, which focuses on developing vaccines against the most prevalent antibiotics resistant bacteria. In his role Jan is also responsible for external partnerships and clinical studies. He holds this function since 2011.
Jan is also a member of the Advisory Board for the Tuberculosis Vaccine Initiative (TBVI), and a member of the Editorial Board for the Expert Review of articles for the journal Vaccines.
From 1986 until 1996, Jan was Head of Vaccines R&D at the National Institute for Public Health and the Environment in the Netherlands (RIVM) and later the Netherlands Vaccines Institute (NVI). In 1997 he moved to industry and was appointed Head & Vice-President Bacterial Vaccines R&D at GSK Biologicals in Belgium. During his tenure, he contributed to the licensure of several vaccines: DTPaHBIPVHib Infanrix-Hexa, DTPaHBIPV Pediarix, Tdap Boostrix, HibMenC-TT Menitorix, 10-valent pneumococcal conjugate Synflorix, HibMenCY-TT Menhibrix, and ACWY-TT Nimenrix.
Jan began his career at the University of Amsterdam (UvA) where he obtained a Master’s degree in Chemistry in 1975 and a PhD on Meningococcal Surface Structure in 1981. In 1982 he was awarded an NIH post-doctoral fellowship research position at the University of Washington in Seattle, USA. In 1983 Jan returned to the UvA as Assistant-Professor Bacteriology. He held this position until 1985.
In his career Jan published over 250 articles in peer-reviewed journals.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
